Latest Healthcare It News

Kingfish Limited’s portfolio edged higher in April, buoyed by strong performances from Mercury and Infratil, while a2 Milk and Summerset weighed on returns amid operational and economic headwinds.

EBR Systems accelerated its U.S. commercial rollout of the WiSE CRT System in Q1 2026 with implant volumes more than doubling and revenue hitting US$2.4 million. The company also secured a key regulatory milestone in Australia with TGA Priority Review, yet losses deepened and cash burn intensified, raising fresh questions about its funding runway.

Enlitic’s Ensight platform goes live at New Zealand’s largest private radiology provider, marking a milestone in its Intelerad partnership and expanding its global footprint after record contract wins.

Bioxyne has locked in a two-year, $50 million exclusive supply agreement with German pharmaceutical distributor ADREXpharma, granting exclusive rights to its Dr Watson® brand in Germany and reinforcing its foothold in Europe’s largest medicinal cannabis market.

dorsaVi has secured a 12-month renewal of its Department of Defense-funded research with Georgia Southern University, advancing real-time gait optimisation to reduce military training injuries and laying groundwork for its exoskeleton and neuromorphic computing strategy.

Pathkey.AI appoints Andrew Farnsworth as CEO, leveraging his defence and AI expertise to drive commercialisation of TrialKey and Chipforge platforms.

CSL Limited’s interim CEO Gordon Naylor reveals a downgraded FY26 outlook amid slower growth and announces substantial impairments tied to CSL Vifor assets. Leadership changes and transformation efforts aim to restore momentum.

Promisia Healthcare’s portfolio value jumps 17.1% to $107.2 million, driven by improved occupancy and operational efficiencies across all sites.

Unith Ltd (ASX:UNT) posted Q3 FY2026 revenue of A$1.26 million, secured a $2 million finance facility to fuel commercial expansion, and showcased significant advancements in its AI Digital Humans platform, including proprietary streaming technology and SDK launches.

Neuren Pharmaceuticals saw a 20% jump in Q1 2026 DAYBUE net sales to US$101 million, with royalties up 23%. The Japan trofinetide trial has been fast-tracked, and the new powder formulation DAYBUE STIX gains early traction.

Zip Co’s April update highlights robust US and ANZ market expansion, with total transaction volume surging and credit losses forecast below 1.75%. The company reconfirms FY26 guidance, underpinned by AI-driven underwriting and new subscription offerings.

Amcor posted a 77% jump in Q3 net sales fueled by the Berry acquisition, delivering synergy gains above expectations and updating fiscal 2026 guidance amid geopolitical headwinds.